Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This review examines the benefits and potential risks of androgen replacement therapy for male hypogonadism but reports no new clinical results; the authors highlight the need for careful risk assessment, especially in older men.

This case report describes a 68-year-old woman with metastatic breast cancer who experienced significant improvement in visual acuity after stopping tamoxifen, which was associated with bilateral optic neuropathies.

In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.

In this study, fraction No. 3 of Oryza sativa bran extract demonstrated high unsaturated fatty acid content and significant 5α-reductase inhibition, suggesting potential for developing anti-androgenic alopecia products.

This review discusses treatment options for androgenetic alopecia in men and women, highlighting minoxidil and finasteride, without presenting new clinical findings.

This article updates the process of care model for evaluating erectile dysfunction, emphasizing comprehensive evaluation and a combination of pharmacotherapy and counseling tailored to patient dynamics.

This paper discusses the potential relationship between finasteride's adverse effects and factors like hand preference and sexual orientation, suggesting these could influence risk in male androgenic alopecia treatment, but reports no new clinical results.

This study suggests that gel containing OSF3 loaded in niosomes offers high transfollicular penetration for topical anti-androgenic alopecia treatment with minimal systemic effect.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This review discusses androgenetic alopecia management with 5α-reductase inhibitors, emphasizing that while dutasteride shows superior efficacy, finasteride is suggested as preferable due to predictable adverse effects and preservation of physiological roles.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This paper presents two cases of rare intraorbital ophthalmic artery aneurysms associated with arteriovenous malformations and discusses their clinical presentation, pathogenesis, and management, but reports no new clinical outcomes.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study found that the risk of persistent sexual dysfunction was higher in men who stopped using finasteride 1 mg compared to omeprazole users.

This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.

This study found that finasteride use was not associated with sexual dysfunction in men with androgenetic alopecia, consistent with other large survey-based controlled studies.

This study reviews the mechanisms by which SARS-CoV-2 may impact male fertility, noting potential disruptions in spermatogenesis and hormone secretion, and underscores the need for follow-up in recovered men.

This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.